Sirigen Group

Healthcare diagnostics tools

Sirigen Group





Deal type

Growth Capital

Investment size

Undisclosed - 3.8x return

Investment date(s)

2010, 2011, 2012 - 2012


The business

  • A portfolio of nine patents including Nobel Prize winning technology with a wide range of applications in research, medical diagnostics and life sciences
  • Highly experienced and entrepreneurial management team with a solid background in life sciences
  • Significant potential to dramatically improve market share in the $49bn diagnostics sector

The strategy

  • Relocate the pioneering technology operations from the USA to the UK and continue to invest in product development
  • Improve financial functions in the firm and commercialise the trademarked technology
  • Build strong strategic partnerships in the UK and USA to grow sales

The developments

  • Attracted a high calibre chair and non-executive director to the business
  • Successfully commercialised the product suite and integrated the technology into a range of products
  • Continued to grow the customer base worldwide
  • Sold to global medical technology firm Becton Dickinson in a $60m+ deal which delivered a 3.8x return for YFM funds
Back to top